GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2
The role of the Global Advisory Committee on Vaccine Safety (GACVS) is to provide independent, expert advice to the World Health Organization on the safety of vaccines.
On January 19 2021 a virtual meeting was held to review all available information on the deaths reported in frail, elderly individuals who had received the Pfizer/BioNTech COVID-19 vaccine. Following this review, it was concluded that vaccination has not contributed to any unexpected or increase in number of fatalities in this patient group. As such, there is no change in recommendations around safety of the Pfizer/BioNTech COVID-19 vaccine.
要了解更多信息，请点击以下链接：
COVID-19 vaccine rollout: Primary care participation in Phase 1b–call for expressions of interest from General Practices
In preparation for the rollout of COVID-19 vaccines in Australia, accredited general practices are invited to express their interest in participating in Phase 1b of the COVID-19 Vaccination Program.
Phase 1b of the COVID-19 Vaccination Program is dedicated to delivering 14.8 million doses of the University of Oxford/AstraZeneca COVID-19 vaccine (dependant on TGA approval).
The Phase 1b priority populations include:
- People aged 70 years and over
- Aboriginal and Torres Strait Islander adults
- Critical and high-risk workers including defence, police, fire, emergency services and meat
processing
- Health care workers other than those prioritised in Phase 1a, including (but not limited to)
hospitals, general practices, pharmacists, allied health, and other healthcare services in the
community
- People at increased risk of severe disease
For further information, including how to register your interest, please follow the link below:
CNN: How some states are administering Covid-19 vaccines at twice the speed of others
Data from the CDC reveals that of the 31 million doses of COVID-19 vaccine that have been distributed to the various jurisdictions in the United States, only 39% (12.2 million doses) have actually been administered. Those states with the highest vaccination rates have suggested that preparation, communication and strategic planning have been vital in vaccine rollout.
要阅读更多信息，请点击以下链接：
CNN: How some states are administering Covid-19 vaccines at twice the speed of others
ABC 电台：尽管有老年人死亡，挪威仍将继续使用辉瑞的新冠疫苗
挪威药品管理局医疗主任 Steinar Madsen 博士接受了 ABC 电台采访，讨论了最近老年人接种辉瑞/BioNTech COVID-19 疫苗后死亡的报道。虽然调查正在进行中，但他强调副作用很少见，挪威将继续使用这种疫苗，作为其 COVID-19 疫苗推广的一部分。
要收听采访，请点击以下链接：
ABC 电台：尽管有老年人死亡，挪威仍将继续使用辉瑞的新冠疫苗
TGA：挪威对老年、非常虚弱患者的 COVID-19 疫苗接种风险进行调查
最近挪威有报道称，接种辉瑞/BioNTech COVID-19 疫苗的 40,000 名老年人中有 30 多人死亡。死亡与接种疫苗后发烧、恶心和腹泻有关。接种疫苗后预计会出现此类不良事件，并且通常是短暂的。记录的死亡病例是非常虚弱的患者，他们的预期寿命只有几周到几个月。
TGA 正在与欧洲监管机构密切合作，进一步调查这些报告，并将确定辉瑞/BioNTech 疫苗的产品信息是否应包含有关体弱、老年人或绝症患者风险的警告。
通过以下链接阅读 TGA 声明的更多内容：
TGA：挪威对老年、非常虚弱患者的 COVID-19 疫苗接种风险进行调查
《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
人口接近 18,000 人的小岛国帕劳已成功摆脱了 COVID-19 疾病的困扰。作为与美国“自由联合”协议的一部分，帕劳可以获得 Moderna COVID-19 疫苗，并计划到 2021 年 4 月实现几乎所有人口的免疫。
要了解更多信息，请点击以下链接：
《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
时代报：我们不能推迟疫苗的推出，冒着冬季患重大疾病的风险
许多科学家呼吁暂停拟议中的 COVID-19 疫苗推广，这是一个令人担忧的问题。
The following article suggests that Australia's initial public health goal should be a rapid vaccine rollout and not herd immunity, in order to limit further risk of major illness. In order to achieve a rapid rollout, both the AstraZeneca and Pfizer COVID-19 vaccines are needed. Recent modelling suggests that vaccination will most likely shift SARS-CoV-2 from a virus causing major disease burden, to a relatively benign coronavirus causing the common cold.
要完整阅读文章，请点击以下链接：
高峰机构支持澳大利亚的 COVID-19 疫苗战略
在 2020 年 1 月 13 日发布的声明中， 澳大利亚传染病协会 (ASID)， 这 澳大利亚感染预防与控制学院 (ACIPC) 和 澳大利亚公共卫生协会 (PHAA) have shown support for the Commonwealth Government's COVID-19 vaccine strategy. The statement suggests that recent media reports surrounding concerns for the ability of any vaccine to create herd immunity is unjustified and reinforces that the public should have confidence in the approach being taken to provide COVID-19 vaccines to Australians.
要完整阅读该声明，请点击以下链接：
Zostavax vaccine: Safety advisory - risk of disseminated varicella zoster virus (vaccine strain) infection
Following a third report of fatal disseminated vaccine strain varicella-zoster virus infection following Zostavax administration, the Therapeutic Goods Administration (TGA) is reminding health professionals that Zostavax should not be used in people with compromised immune function.
Further details on the alert can be seen here:
Zostavax vaccine: Safety advisory
For more information on Zostavax® and access to the Zostavax® GP decision aid please review the MVEC pages below:
微血管内皮细胞： 带状疱疹
微血管内皮细胞： Zoster vaccine (Zostavax®) FAQ’s